ArticleInternational archives of occupational and environmental health2014
Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines.
Article in International archives of occupational and environmental health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- The health economics of bladder cancer: an updated review of the published literature.PharmacoEconomics · 2014Pooled it
- Effect of frailty status and histopathological features on upstaging of non-muscle-invasive bladder cancer: a critical analysis based on machine learning.International urology and nephrology · 2026Article
- Evaluation of variations in urine laminin-γ2 monomer in non-muscle-invasive bladder cancer before and after transurethral resection of the bladder tumor.BMC cancer · 2026Article
- Developing a prediction model in a large case-control study for the early detection of bladder cancer.Journal of translational medicine · 2025Article
- Review
- 5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data.World journal of urology · 2023Article
- How Does Environmental and Occupational Exposure Contribute to Carcinogenesis in Genitourinary and Lung Cancers?Cancers · 2023Review
- Differential Expression of LncRNA in Bladder Cancer Development.Diagnostics (Basel, Switzerland) · 2023Article
- Multiple directional DWI combined with T2WI in predicting muscle layer and Ki-67 correlation in bladder cancer in 3.0-T MRI.Cancer medicine · 2023Article
- Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice.Nature reviews. Clinical oncology · 2023Review
- Incidental Diagnosis of Urothelial Bladder Cancer: Associations with Overall Survival.Cancers · 2023Article
- Article
- Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019.Military Medical Research · 2021Article
- Review
- UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives.Translational andrology and urology · 2021Review
- Current updates on the role of reactive oxygen species in bladder cancer pathogenesis and therapeutics.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.EBioMedicine · 2020Article
- Bone morphogenic proteins-2, -4, -6 and 7 in non-muscle invasive bladder cancer.Oncology letters · 2020Article
- Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin - a case-control comparison nested into a prospective cohort of asbestos-exposed workers.Scientific reports · 2018Article
- Evaluation of a New Survivin ELISA and UBCInternational journal of molecular sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo validate urinary markers for the early detection of bladder cancer (BC) in chemical workers.
methodsUroScreen was conducted as a validation study for tumor markers within the frame of a health surveillance program of the German Social Accident Insurance for active or retired workers with former exposure to aromatic amines. From 2003 to 2010, 1,609 men took part in voluntary annual screens. Cytology, the quantitative NMP22(®) assay, and UroVysion™ were applied to 7,091 urine samples.
resultsFifteen out of 21 tumors were detected following test positivity. The UroVysion/NMP22 panel detected 14 out of 21 tumors versus 8 tumors with cytology alone (sensitivity 66.7 vs. 44.4 %, specificity 94.5 vs. 98.5 %). The sensitivity of the panel increased to 85.7 % in samples collected ≤12 months before diagnosis and when papillomas were excluded, compared to 58.3 % with cytology. About 3 % of NMP22 tests were false-positive. UroVysion results overlapped with cytology due to the preselection of atypical cells. NMP22 was less and UroVysion more frequently positive in diluted urine samples. Leukocytes confounded NMP22 but not UroVysion. The low incidence of BC in this study population yielded low positive predictive values of the markers and high costs per tumor detected with screening.
conclusionsUroVysion in combination with NMP22 detected more cases than cytology alone, at the expense of a lower specificity. High costs per detected case resulted from a lower BC incidence than in the past when levels of occupational exposure to aromatic amines were higher. Currently, it cannot be recommended to apply these markers for screening in asymptomatic workers. The increase in sensitivity is not balanced by the high costs of UroVysion and the false-positive tests of NMP22.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.